CCL2 and chronic obstructive pulmonary disease: This may open the opportunity of studying new anti-inflammatory drugs in COPD, such as steroids, β2-agonists, or anti-MCP-1 monoclonal antibody (controlling monocyte recruitment) [27], [58].